-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $9

Benzinga·12/22/2025 12:19:24
语音播报
Jefferies analyst Farzin Haque initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $9.